methohexital sodium
- Product Name
- methohexital sodium
- CAS No.
- 309-36-4
- Chemical Name
- methohexital sodium
- Synonyms
- Lilly 22451;Brevimytal.;Brevital sodium;Enallynymal sodium;SODIUMMETHOHEXITAL;methohexital sodium;methohexitone sodium;METHOHEXITAL SODIUMQ: What is METHOHEXITAL SODIUM Q: What is the CAS Number of METHOHEXITAL SODIUM;2,4,6(1H,3H,5H)-Pyrimidinetrione,1-methyl-5-(1-methyl-2-pentyn-1-yl)-5-(2-propen-1-yl)-, sodium salt (1:1)
- CBNumber
- CB0875235
- Molecular Formula
- C14H18N2O3.Na
- Formula Weight
- 285.29
- MOL File
- 309-36-4.mol
methohexital sodium Property
- CAS DataBase Reference
- 309-36-4
- EPA Substance Registry System
- Methohexital sodium (309-36-4)
Safety
- RIDADR
- 3249
- HazardClass
- 6.1(b)
- PackingGroup
- III
N-Bromosuccinimide Price
- Product number
- M260663
- Product name
- Methohexital
- Packaging
- 50mg
- Price
- $60
- Updated
- 2021/12/16
- Product number
- API0008934
- Product name
- METHOHEXITAL SODIUM
- Purity
- 95.00%
- Packaging
- 5MG
- Price
- $503.72
- Updated
- 2021/12/16
methohexital sodium Chemical Properties,Usage,Production
Description
Methohexital sodium, sodium 5-allyl-1-methyl-5-(1-methyl-2-pentynyl)- barbiturate, The free acid forms colorless crystals, mp 6 0 – 6 4?C. It is prepared by condensing diethyl allyl(1-methyl-2-pentynyl)malonate with N-methylurea .
Originator
Brevital,Lilly,US,1960
Uses
Amobarbital is used as anesthetics for perioperative sedation as well as in the short-term treatment of insomnia, anxiety, psychosis, control of seizures, and alcohol withdrawal. These agents are also exploited in abuse settings. Abuse of barbiturates started in the 1940s as they were liberally given to military personnel stationed in the South Pacific in order to help them cope with harsh conditions. They were called ‘goofballs’ in this context. After World War II, many servicemen needed detoxification and treatment for barbiturate dependence upon returning to the United States. Reported barbiturate abuse peaked in the 1970s, but has since declined with the increased use of other sedatives such as benzodiazepines. Use of certain long-acting barbiturates as anticonvulsants, however, continues. Phenobarbital is currently the most commonly prescribed anticonvulsant in use worldwide. Pentobarbital has been used in the United States for lethal injection during executions. Phenobarbital is also used for the treatment of alcohol withdrawal and compares favorably to other agents including benzodiazepines.
Uses
Anesthetic (intravenous).
Definition
ChEBI: The sodium salt of methohexital.
Manufacturing Process
Preparation of 3-Hexyne-2-ol: A solution of ethyl magnesium bromide was prepared by the reaction of 229 g of ethyl bromide and 48.6 g of magnesium in 750 ml of anhydrous ether. To the ether solution was then added with stirring a solution of 108 g of ethyl acetylene in 250 ml of cold anhydrous ether. The addition required approximately 3 hours, and the mixture was stirred and refluxed for a further period of 3? hours. Thereafter there was added to the reaction mixture a solution of 88 g of freshly distilled acetaldehyde in 170 ml of anhydrous ether, over a period of about 45 minutes and at a temperature in the range of about -10° to 0°C.
The resulting reaction mixture was poured over about 1 kg of crushed ice, and
neutralized with 10% aqueous hydrochloric acid. The organic phase of the
resulting mixture was separated, and the aqueous phase was extracted 3
times with 250 ml portions of ether. The combined organic phase and ether
washings were washed twice with water and dried over anhydrous potassium
carbonate. The dried ether solution was fractionally distilled, and the 3-
hexyne-2-ol formed in the reaction was collected as a fraction boiling at about
79° to 80°C at the pressure of 60 mm of mercury.
Preparation of 2-Bromo-3-Hexyne: A solution of 138 g of 3-hexyne-2-ol and 9
g of pyridine in 138 ml of anhydrous ether was treated with 175 g of
phosphorus tribromide, added dropwise over a period of about 20 minutes at
a temperature of about -10°C. The reaction mixture was permitted to come to
room temperature while stirring for about 3 hours, and was then heated to
refluxing for about 1 hour. After cooling, the reaction mixture was poured over
about 50 g of crushed ice. A two-phase system formed, and the ether layer
was separated, washed with dilute sodium bicarbonate solution, dried over
anhydrous potassium carbonate and fractionally distilled. The 2-bromo-3-
hexyne formed in the reaction was collected at 75°C at the pressure of 50
mm of mercury.
Preparation of Diethyl (1-Methyl-2-Pentynyl) Malonate: To a solution of 28.6 g
of sodium in 430 ml of absolute ethanol were added 200 g of diethyl
malonate. About half of the alcohol was removed by distillation in vacuo, and
thereafter a solution of 200 g of 2bromo-3-hexyne in 100 ml of anhydrous
ether was added slowly to the reaction mixture.
The heat of reaction brought about refluxing during the addition of the 2-
bromo-3-hexyne, and when the addition was complete the reaction mixture
was heated to refluxing for a further period of 30 minutes. A sufficient amount
of water was then added to the reaction mixture to dissolve the sodium
bromide which had formed, and the only organic layer was separated, washed
with water and dried over anhydrous magnesium sulfate. The dried organic
layer was then fractionally distilled under reduced pressure, and the diethyl
(1-methyl-2-pentynyl) malonate formed in the reaction was collected at about
117° to 120°C at the pressure of 2 mm of mercury.
Preparation of Diethyl Allyl (1-Methyl-2-Pentynyl) Malonate: A solution of 12.1
g of sodium in 182 ml of absolute ethanol was prepared, and thereto were
added 126.6 g of diethyl (1-methyl-2-pentynyl) malonate. Most of the ethanol
was then distilled off under reduced pressure, and the residue was cooled and
63.5 g of allyl bromide were slowly added thereto. After completion of the
addition, the mixture was refluxed for about 1 hour. The reaction mixture was
cooled, treated with about 100 ml of water, and the oily organic layer which
formed was removed, washed with water and dried over anhydrous
magnesium sulfate. The dried oily organic material was fractionally distilled in
vacuo, and diethyl allyl (1-methyl-2-pentynyl) malonate boiling at 105° to
107°C at the pressure of 1 mm of mercury was recovered.
Preparation of 1-Methyl-5-Allyl-5-(1-Methyl-2-Pentynyl) Barbituric Acid: A
solution of 23.8 g of sodium in 360 ml of absolute alcohol was prepared and
thereto were added 38.3 g of methyl urea and 96.8 g of diethyl allyl (1-
methyl-2-pentynyl) malonate. The mixture was refluxed for about 20 hours,
cooled, and the ethanol was removed by distillation in vacuo. The residue was
dissolved in about 300 ml of water and the aqueous solution was washed with
ether, and the washings were discarded. The aqueous solution was then
acidified with acetic acid, and extracted with three 150 ml of portions of ether.
The combined ether extracts were washed with 5% aqueous sodium
bicarbonate solution, dried over anhydrous sodium sulfate, and fractionally
distilled in vacuo. The fraction boiling at about 145 to 150°C at the pressure
of 0.5 mm of mercury, weighing 61 g and consisting of 1-methyl-5-allyl-5-(1-
methyl-2-pentynyl) barbituric acid, was collected. The only distillate was
substantially pure, and could be used as such in pharmaceutical preparation
or a salt could be prepared therefrom according to the procedures disclosed
hereinafter. On standing, the oil crystallized. The crystalline 1-methyl-5-allyl5-(1-methyl-2-pentynyl) barbituric acid melted at about 60° to 64°C after
recrystallization from dilute ethanol.
Preparation of Sodium 1-Methyl-5-Allyl-5-(1-Methyl-2-Pentynyl) Barbiturate: A
solution of 61 g of 1-methyl-5-allyl-5-(1-methyl-2-pentynyl) barbituric acid in
100 ml of ether was extracted with 465 ml of 2% aqueous sodium hydroxide
solution. The aqueous extract was washed with successive 75 ml and 50 ml
portions of ether. The pH of the aqueous solution was adjusted to 11.7, using
5% aqueous sodium hydroxide solution. 5 g of decolorizing carbon were
added to the solution with stirring; the mixture was permitted to stand for 20
minutes at room temperature, and the carbon was removed by filtration. A
solution containing 4 g of sodium carbonate in 25 ml of water was added to
the aqueous solution, and the mixture was filtered sterile through a porcelain
filter candle of 02 porosity into sterile bottles. The aqueous solution was then
dried from the frozen state, whereupon a sterile residue of sodium 1-methyl-5-allyl-5-(1-methyl-2-pentynyl) barbiturate, weighing about 62 g was
obtained.
brand name
Brevital Sodium (King).
Therapeutic Function
Anesthetic
General Description
White powder.
Air & Water Reactions
Water soluble.
Reactivity Profile
Solutions of methohexital sodium are incompatible with silicone and acid. .
Fire Hazard
Flash point data are not available for methohexital sodium, but methohexital sodium is probably combustible.
Clinical Use
Methohexital sodium is a short-acting anesthetic administered intravenously. It is very potent and has the shortest duration of action among the barbiturates used. A disturbing factor is that rather frequently it causes hiccups directly after injection. Patients are reported to recover rapidly from anesthesia. Abuse can lead to addiction.
Safety Profile
Poison by intravenous and implant routes. Human systemic effects by intravenous route: blood pressure lowering, gastrointestinal effects, and allergc dermatitis. An FDA proprietary drug. Cazltion: Excessive use may lead to addction or habituation. Allergenic effects by intravenous route. When heated to decomposition it emits toxic fumes of Na2O and NOx. See also BARBITURATES.
Veterinary Drugs and Treatments
Methohexital is sometimes used in small animals as an ultrashort acting anesthetic agent, but, propofol has largely supplanted methohexital’s use in small animals. However, because it is not dependent on redistribution to fat to reverse its effect, it may be useful in canine sight hound breeds. Because methohexital can induce anesthesia very rapidly, it may also be useful when general anesthesia must be administered to a patient with a full stomach, as an ET tube may be placed rapidly before aspiration of vomitus can occur.